US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Insight Molecular Diagnostics Inc.

4.34

0.0000

Volume:64.72K

Turnover:278.42K

Market Cap:142.02M

PE:-2.96

High:4.46

Open:4.37

Low:4.23

Close:4.34

52wk High:8.51

52wk Low:2.33

Shares:32.72M

Float Shares:10.41M

Volume Ratio:0.53

T/O Rate:0.62%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.4638

EPS(LYR):-1.6500

ROE:-23603.11%

ROA:-57.82%

PB:-6.67

PE(LYR):-2.63

Loading ...

Overview Company News Filings

We're Keeping An Eye On Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Rate

Simply Wall St.

Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX)

Insight Molecular Diagnostics Inc reports results for the quarter ended March 31 - Earnings Summary

Insight Molecular Diagnostics Q1 FY26 net loss narrows to $4.29 million; revenue drops to $32,000

Insight Molecular Diagnostics amends 8-K, reclassifies Quest agreement disclosure to Item 8.01

Insight Molecular Q1 Adj. EPS $(0.28) Misses $(0.26) Estimate, Sales $32.000K Miss $300.000K Estimate

Benzinga Earnings

Imdx Reports Q1 2026 Results and Update on Progress Toward Graftassure Commercialization

THOMSON REUTERS

Insight Molecular Diagnostics Inc Q1 Pretax Profit USD -4.29 Million

THOMSON REUTERS

Press Release: IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization

Insight Molecular Diagnostics Inc expected to post a loss of 26 cents a share - Earnings Preview

Insight Molecular Diagnostics schedules Q1 2026 results webcast

Insight Molecular refiles bylaws exhibit after clerical error in 10-K attachment

Broadwood Partners buys 570,184 Insight Molecular Diagnostics shares for $2.04 million

Broadwood Partners buys $633,117 Insight Molecular Diagnostics shares

Insight Molecular Diagnostics highlights new real-world GraftAssure data at EFI2026

Analysts Are Bullish on Top Healthcare Stocks: Insight Molecular Diagnostics (IMDX), Tango Therapeutics (TNGX)

Buy Rating on IMDX Driven by Strong GraftAssure Traction, Upcoming FDA Catalyst, and Solid Balance Sheet

Insight Molecular Q4 Adj. EPS $(0.27) Misses $(0.24) Estimate, Sales $1.139M Down From $1.486M Last Year

Benzinga Earnings

Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million

Insight Molecular Diagnostics Inc - Reports Q4 2025 Net Loss of $23.0 Mln or $0.72 per Share

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/IMDX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMDX\",,,,,undefined,":{"symbol":"IMDX","market":"US","secType":"STK","nameCN":"Insight Molecular Diagnostics Inc.","latestPrice":4.34,"timestamp":1787598164620,"preClose":4.34,"halted":0,"volume":64715,"delay":0,"changeRate":0,"floatShares":10405400,"shares":32724284,"eps":-1.463822,"marketStatus":"Trading","change":0,"latestTime":"08-24 15:03:29 EDT","open":4.37,"high":4.4626,"low":4.23,"amount":278416.35527999996,"amplitude":0.053594,"askPrice":4.34,"askSize":246,"bidPrice":4.3,"bidSize":55,"shortable":3,"etf":0,"ttmEps":-1.463822,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":4.34,"preHourTrading":{"tag":"盘前","latestPrice":4.36,"preClose":4.34,"latestTime":"09:26 EDT","volume":643,"amount":2880.150034,"timestamp":1787577996909,"change":0.02,"changeRate":0.004608,"amplitude":0.062212},"postHourTrading":{"tag":"盘后","latestPrice":4.34,"preClose":4.34,"latestTime":"16:10 EDT","volume":710,"amount":3081.4,"timestamp":1787343004724,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.529981,"impliedVol":8.3361,"impliedVolPercentile":0.9026},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMDX\",,,,,undefined,":{"symbol":"IMDX","floatShares":10405400,"roa":"-57.82%","roe":"-23603.11%","lyrEps":-1.65,"volumeRatio":0.529981,"shares":32724284,"dividePrice":0,"high":4.4626,"amplitude":0.053594,"preClose":4.34,"low":4.23,"week52Low":2.33,"pbRate":"-6.67","psRate":"85.04","week52High":8.51,"institutionHeld":0,"latestPrice":4.34,"committee":-0.634551,"eps":-1.463822,"divideRate":0,"volume":64715,"delay":0,"ttmEps":-1.463822,"open":4.37,"prevYearClose":7.5,"prevWeekClose":4.34,"prevMonthClose":4.65,"prevQuarterClose":5.9,"fiveDayClose":4.27,"twentyDayClose":4.7,"sixtyDayClose":6.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMDX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-10","symbol":"IMDX","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786334400000,"reportTimeType":"post","actualEps":-0.23},{"market":"US","date":"2026-05-13","symbol":"IMDX","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778644800000,"reportTimeType":"post","actualEps":-0.28},{"market":"US","date":"2026-03-26","symbol":"IMDX","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2025-11-10","symbol":"IMDX","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"post","actualEps":-0.34},{"market":"US","date":"2025-08-11","symbol":"IMDX","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":-0.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMDX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IMDX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1743220800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IMDX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IMDX","date":"2026-08-21","current":-2.964841,"percent":0.467577,"low":-4.420615,"twenty":-3.335591,"median":-2.772491,"eighty":-1.488804,"high":-1.083107,"avg":-2.577338,"sd":0.887337,"marketCap":140714421},"quantilePoints":[{"date":"2025-06-20","current":-1.55268,"twenty":-1.55268,"median":-1.55268,"eighty":-1.55268,"marketCap":90373740},{"date":"2025-06-27","current":-1.655864,"twenty":-1.798357,"median":-1.675518,"eighty":-1.638667,"marketCap":96379590},{"date":"2025-07-03","current":-1.40036,"twenty":-1.71581,"median":-1.6055,"eighty":-1.491752,"marketCap":81507962},{"date":"2025-07-11","current":-1.420014,"twenty":-1.663726,"median":-1.493717,"eighty":-1.427876,"marketCap":82651933},{"date":"2025-07-18","current":-1.390533,"twenty":-1.642106,"median":-1.471607,"eighty":-1.399377,"marketCap":80935976},{"date":"2025-07-25","current":-1.454409,"twenty":-1.585601,"median":-1.459323,"eighty":-1.399377,"marketCap":84653883},{"date":"2025-08-01","current":-1.238213,"twenty":-1.556611,"median":-1.424927,"eighty":-1.390533,"marketCap":72070198},{"date":"2025-08-08","current":-1.289805,"twenty":-1.50551,"median":-1.405274,"eighty":-1.357121,"marketCap":75073123},{"date":"2025-08-15","current":-1.083107,"twenty":-1.489787,"median":-1.40036,"eighty":-1.288331,"marketCap":68687397},{"date":"2025-08-22","current":-1.119211,"twenty":-1.488804,"median":-1.395447,"eighty":-1.253936,"marketCap":70976977},{"date":"2025-08-29","current":-1.132749,"twenty":-1.484873,"median":-1.380706,"eighty":-1.161632,"marketCap":71835569},{"date":"2025-09-05","current":-1.114698,"twenty":-1.480942,"median":-1.363484,"eighty":-1.138165,"marketCap":70690780},{"date":"2025-09-12","current":-1.435117,"twenty":-1.467185,"median":-1.353884,"eighty":-1.132749,"marketCap":91010801},{"date":"2025-09-19","current":-1.520863,"twenty":-1.485856,"median":-1.368397,"eighty":-1.138165,"marketCap":96448554},{"date":"2025-09-26","current":-1.47122,"twenty":-1.485856,"median":-1.389987,"eighty":-1.149898,"marketCap":93300381},{"date":"2025-10-03","current":-1.507324,"twenty":-1.490769,"median":-1.392517,"eighty":-1.163437,"marketCap":95589961},{"date":"2025-10-10","current":-1.714919,"twenty":-1.500103,"median":-1.395447,"eighty":-1.171561,"marketCap":108755046},{"date":"2025-10-17","current":-2.087237,"twenty":-1.528084,"median":-1.402817,"eighty":-1.173366,"marketCap":132366339},{"date":"2025-10-24","current":-2.897311,"twenty":-1.598867,"median":-1.417558,"eighty":-1.192321,"marketCap":183738788},{"date":"2025-10-31","current":-2.67392,"twenty":-1.674528,"median":-1.432479,"eighty":-1.204957,"marketCap":169572012},{"date":"2025-11-07","current":-2.933415,"twenty":-1.775372,"median":-1.457682,"eighty":-1.224911,"marketCap":186028368},{"date":"2025-11-14","current":-3.696486,"twenty":-2.084901,"median":-1.473476,"eighty":-1.250005,"marketCap":224665029},{"date":"2025-11-21","current":-2.862765,"twenty":-2.669859,"median":-1.478977,"eighty":-1.260815,"marketCap":173993132},{"date":"2025-11-28","current":-2.895779,"twenty":-2.764631,"median":-1.48389,"eighty":-1.270643,"marketCap":175999643},{"date":"2025-12-05","current":-2.631669,"twenty":-2.764631,"median":-1.488804,"eighty":-1.282435,"marketCap":159947558},{"date":"2025-12-12","current":-2.452451,"twenty":-2.743778,"median":-1.493785,"eighty":-1.285383,"marketCap":149055072},{"date":"2025-12-19","current":-2.447735,"twenty":-2.714849,"median":-1.505068,"eighty":-1.294719,"marketCap":148768428},{"date":"2025-12-26","current":-2.744859,"twenty":-2.739199,"median":-1.51635,"eighty":-1.307003,"marketCap":166827023},{"date":"2026-01-02","current":-3.537189,"twenty":-2.766436,"median":-1.545684,"eighty":-1.326657,"marketCap":214983277},{"date":"2026-01-09","current":-3.537189,"twenty":-2.848616,"median":-1.572334,"eighty":-1.341398,"marketCap":214983277},{"date":"2026-01-16","current":-3.122159,"twenty":-2.895779,"median":-1.658314,"eighty":-1.353884,"marketCap":189758572},{"date":"2026-01-23","current":-3.150456,"twenty":-2.900495,"median":-1.677968,"eighty":-1.357494,"marketCap":191478439},{"date":"2026-01-30","current":-3.122159,"twenty":-2.986727,"median":-1.755536,"eighty":-1.360521,"marketCap":189758572},{"date":"2026-02-06","current":-3.155173,"twenty":-3.018554,"median":-1.819819,"eighty":-1.364943,"marketCap":191765083},{"date":"2026-02-13","current":-2.951395,"twenty":-3.074996,"median":-2.083343,"eighty":-1.369886,"marketCap":179379897},{"date":"2026-02-20","current":-2.87381,"twenty":-3.072166,"median":-2.244936,"eighty":-1.382344,"marketCap":174664420},{"date":"2026-02-27","current":-3.000829,"twenty":-3.054013,"median":-2.378582,"eighty":-1.390315,"marketCap":182384395},{"date":"2026-03-06","current":-2.900272,"twenty":-3.054013,"median":-2.405289,"eighty":-1.390533,"marketCap":176272748},{"date":"2026-03-13","current":-2.588017,"twenty":-3.035708,"median":-2.450093,"eighty":-1.392913,"marketCap":157294478},{"date":"2026-03-20","current":-2.074647,"twenty":-3.019142,"median":-2.42887,"eighty":-1.395068,"marketCap":126092915},{"date":"2026-03-27","current":-2.175204,"twenty":-3.007939,"median":-2.401676,"eighty":-1.395447,"marketCap":132204561},{"date":"2026-04-02","current":-2.203374,"twenty":-3.005074,"median":-2.393547,"eighty":-1.397412,"marketCap":110657844},{"date":"2026-04-10","current":-2.03684,"twenty":-3.002883,"median":-2.367559,"eighty":-1.40036,"marketCap":102294170},{"date":"2026-04-17","current":-2.24821,"twenty":-2.997331,"median":-2.315182,"eighty":-1.402326,"marketCap":112909602},{"date":"2026-04-24","current":-2.254615,"twenty":-2.992083,"median":-2.318101,"eighty":-1.405274,"marketCap":113231282},{"date":"2026-05-01","current":-2.568468,"twenty":-2.989405,"median":-2.378582,"eighty":-1.410188,"marketCap":128993591},{"date":"2026-05-08","current":-3.176958,"twenty":-2.997331,"median":-2.400572,"eighty":-1.41854,"marketCap":159553170},{"date":"2026-05-15","current":-4.332878,"twenty":-3.023006,"median":-2.404034,"eighty":-1.423945,"marketCap":207289210},{"date":"2026-05-22","current":-3.96843,"twenty":-3.074996,"median":-2.408339,"eighty":-1.431951,"marketCap":189853669},{"date":"2026-05-29","current":-4.407117,"twenty":-3.122159,"median":-2.447735,"eighty":-1.438975,"marketCap":210840894},{"date":"2026-06-05","current":-4.420615,"twenty":-3.146683,"median":-2.45635,"eighty":-1.455064,"marketCap":211486655},{"date":"2026-06-12","current":-3.664724,"twenty":-3.159245,"median":-2.45958,"eighty":-1.45801,"marketCap":175324051},{"date":"2026-06-18","current":-3.590484,"twenty":-3.201673,"median":-2.518479,"eighty":-1.459323,"marketCap":171772367},{"date":"2026-06-26","current":-3.772957,"twenty":-3.230633,"median":-2.562063,"eighty":-1.47122,"marketCap":180502033},{"date":"2026-07-02","current":-3.840452,"twenty":-3.255363,"median":-2.59331,"eighty":-1.47483,"marketCap":183731050},{"date":"2026-07-10","current":-3.273496,"twenty":-3.306599,"median":-2.614479,"eighty":-1.477539,"marketCap":156607309},{"date":"2026-07-17","current":-3.179003,"twenty":-3.306599,"median":-2.644897,"eighty":-1.47878,"marketCap":152086686},{"date":"2026-07-24","current":-3.34774,"twenty":-3.348171,"median":-2.67392,"eighty":-1.479992,"marketCap":160159228},{"date":"2026-07-31","current":-3.104759,"twenty":-3.335591,"median":-2.690166,"eighty":-1.482432,"marketCap":148534768},{"date":"2026-08-07","current":-3.239748,"twenty":-3.35124,"median":-2.73071,"eighty":-1.484411,"marketCap":154992801},{"date":"2026-08-14","current":-2.459675,"twenty":-3.348603,"median":-2.744859,"eighty":-1.487186,"marketCap":121407093},{"date":"2026-08-21","current":-2.850836,"twenty":-3.335591,"median":-2.772491,"eighty":-1.488804,"marketCap":140714421}],"updateTime":1787569136943},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMDX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635108954","title":"We're Keeping An Eye On Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635108954","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635108954?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:52","pubTimestamp":1778842330,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imdx/insight-molecular-diagnostics/news/were-keeping-an-eye-on-insight-molecular-diagnostics-nasdaqi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imdx/insight-molecular-diagnostics/news/were-keeping-an-eye-on-insight-molecular-diagnostics-nasdaqi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QQQ","QQQJ","NVIW.SI",".IXIC","SQQQ","FTEC","PSQ","JEPQ","TECS","ONEQ","MNQmain","IYW","QYLG","BK4139","IMDX","QQQE","GPIQ","NDX","QID","QQQM","QQQY","QQQA","TQQQ","NQmain","TQQY","QDTE","QLD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635486487","title":"Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635486487","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635486487?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:19","pubTimestamp":1778764768,"startTime":"0","endTime":"0","summary":"In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Insight Molecular Diagnostics, with a price target of $12.00....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lake-street-remains-a-buy-on-insight-molecular-diagnostics-imdx-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lake-street-remains-a-buy-on-insight-molecular-diagnostics-imdx-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635527557","title":"Insight Molecular Diagnostics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635527557","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635527557?lang=en_us&edition=fundamental","pubTime":"2026-05-14 08:01","pubTimestamp":1778716866,"startTime":"0","endTime":"0","summary":"Insight Molecular Diagnostics Inc reports results for the quarter ended March 31 - Earnings SummaryInsight Molecular Diagnostics Inc IMDX.OQ reported a quarterly adjusted loss of 12 cents per share fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R000:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDIT","IMDX","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635536537","title":"Insight Molecular Diagnostics Q1 FY26 net loss narrows to $4.29 million; revenue drops to $32,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2635536537","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635536537?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:14","pubTimestamp":1778703254,"startTime":"0","endTime":"0","summary":"Insight Molecular Diagnostics posted Q1 2026 revenue of USD 32,000, down from USD 2.14 million a year earlier, while net loss narrowed to USD 4.29 million, or USD 0.12 per share.Gross profit fell to USD 15,000, producing a 46.9% gross margin; operating loss narrowed to USD 4.41 million.Cash, cash equivalents, and restricted cash rose to USD 29.36 million at quarter-end following a USD 26.02 million registered direct offering completed in February.FDA review of GraftAssureDx began after a late-March submission, with management still targeting marketing authorization later in 2026; 34 U.S. transplant centers have expressed interest in its GALACTIC registry, with a top-10 Northeast kidney transplant center signing the first trial agreement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL1G1Bpp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMDX","MDIT","BK4139","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758217","title":"Insight Molecular Diagnostics amends 8-K, reclassifies Quest agreement disclosure to Item 8.01","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758217","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758217?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:06","pubTimestamp":1778702794,"startTime":"0","endTime":"0","summary":"Insight Molecular Diagnostics filed Form 8-K/A to correct its Feb. 20, 2026 report on a specimen collection agreement with Quest Diagnostics.Amendment reclassifies that disclosure under Item 8.01, with no change to underlying agreement announcement tied to GraftAssureCore test services.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL5CJf8z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4567","LU0823417737.USD","BK4139","LU2506951875.HKD","LU2506952097.USD","BK4588","LU0950375773.USD","LU0823417653.USD","BK4196","LU1854103824.USD","IMDX","BK4585","LU1854104046.USD","MDIT","DGX","LU2506951958.HKD","LU2506952170.USD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635775878","title":"Insight Molecular Q1 Adj. EPS $(0.28) Misses $(0.26) Estimate, Sales $32.000K Miss $300.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635775878","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635775878?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:06","pubTimestamp":1778702784,"startTime":"0","endTime":"0","summary":"Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 47.37 percent decrease over losses of $(0.19) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52542962/insight-molecular-q1-adj-eps-0-28-misses-0-26-estimate-sales-32-000k-miss-300-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Insight Molecular Q1 Adj. EPS $(0.28) Misses $(0.26) Estimate, Sales $32.000K Miss $300.000K Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635581587","title":"Imdx Reports Q1 2026 Results and Update on Progress Toward Graftassure Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2635581587","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635581587?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702702,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUA5VJH14:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758171","title":"Insight Molecular Diagnostics Inc Q1 Pretax Profit USD -4.29 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758171","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758171?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702702,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLXDA8FF1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758226","title":"Press Release: IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758226","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758226?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702700,"startTime":"0","endTime":"0","summary":"-- Progressing toward commercialization with third-party head-to-head data. first to sign clinical trial agreement to participate in GALACTIC study. -- Booked research-use-only purchase by E.U. transplant center and APAC. Meanwhile, the GraftAssureIQ research-use-only pilot program that launched in summer 2024 is beginning to produce tangible results. So far in the second quarter, we have seen new traction with one small commercial order outside of the U.S. and another that we expect soon. This summer, we expect to achieve our first significant U.S. order of GraftAssureIQ from a major transplant hospital.Researchers and laboratory clinicians enjoy this type of exploration. Our future potential customers are highly engaged and passionate about t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","BK4139","ATC","IMDX","BK4585","LABU","BK4109","PRGS","BK4097","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634625665","title":"Insight Molecular Diagnostics Inc  expected to post a loss of 26 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634625665","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634625665?lang=en_us&edition=fundamental","pubTime":"2026-05-12 07:02","pubTimestamp":1778540522,"startTime":"0","endTime":"0","summary":"Insight Molecular Diagnostics Inc  expected to post a loss of26cents a share - Earnings Preview Insight Molecular Diagnostics Inc IMDX.OQ IMDX.O is expected to  show a fall in quarterly revenue when i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O2TU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDIT","BK4139","IMDX","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633528801","title":"Insight Molecular Diagnostics schedules Q1 2026 results webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2633528801","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633528801?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:23","pubTimestamp":1778099018,"startTime":"0","endTime":"0","summary":"Insight Molecular Diagnostics schedules Q1 2026 results for May 13, 2026, with release set for market close.Zoom webinar on May 13, 2026 at 5:00 pm ET to discuss results, followed by Q&A; registration via link.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDLbCvhgY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4112","SG9999014039.USD","IE00BN0W2V16.EUR","BK4139","IE00BN0W2T93.GBP","MDIT","IE00B64PRP62.GBP","SG9999014005.SGD","LU2095319765.USD","IMDX","SG9999014013.SGD","LU2210150020.SGD","SG9999014021.USD","IE00BKPKM429.USD","LU0314104364.USD","BK4082","IE00BGHQF748.EUR","NDAQ","BK4585","BK4588","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632661335","title":"Insight Molecular refiles bylaws exhibit after clerical error in 10-K attachment","url":"https://stock-news.laohu8.com/highlight/detail?id=2632661335","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632661335?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:42","pubTimestamp":1777581774,"startTime":"0","endTime":"0","summary":"Insight Molecular Diagnostics filed a Form 8-K to correct an exhibit included with its annual report on Form 10-K for fiscal 2025.Exhibit 3.5 inadvertently contained shareholder voting provisions that were not part of company bylaws due to a clerical error.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL7HvP3Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMDX","BK4139","BK4082","MDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630469643","title":"Broadwood Partners buys 570,184 Insight Molecular Diagnostics shares for $2.04 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2630469643","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630469643?lang=en_us&edition=fundamental","pubTime":"2026-04-28 07:09","pubTimestamp":1777331346,"startTime":"0","endTime":"0","summary":"Broadwood Partners reported open-market purchases totaling 570,184 Insight Molecular Diagnostics common shares at prices between $3.50 and $3.64.Neal C. Bradsher, president of Broadwood Capital, reported direct ownership of 157 shares.Broadwood Partners reported warrants to purchase 150,093 common shares at an exercise price of $30.60.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 27, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDLwpFs4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMDX","MDIT","BK4082","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629772561","title":"Broadwood Partners buys $633,117 Insight Molecular Diagnostics shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2629772561","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629772561?lang=en_us&edition=fundamental","pubTime":"2026-04-21 07:24","pubTimestamp":1776727486,"startTime":"0","endTime":"0","summary":"Broadwood Partners reported additional purchases of Insight Molecular Diagnostics common stock.Filing also showed 150,093 warrants to purchase common stock at USD 30.6 per share.Neal C. Bradsher, President of Broadwood Capital, held 157 shares directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL53rkSZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMDX","BK4082","MDIT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627044527","title":"Insight Molecular Diagnostics highlights new real-world GraftAssure data at EFI2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2627044527","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627044527?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:11","pubTimestamp":1776168661,"startTime":"0","endTime":"0","summary":"Insight Molecular Diagnostics flagged new independent real-world head-to-head findings supporting its GraftAssure transplant assay.Results were already presented at 39th European Immunogenetics and Histocompatibility Conference  on April 21-24, 2026.Additional clinical evidence is scheduled for presentation at 63rd European Renal Association Congress on June 3-6, 2026, followed by American Transplant Congress on June 20-24, 2026.Data are positioned to strengthen clinical adoption case for localized testing model, supporting push into roughly $2 billion market for kitted transplant rejection testing.Regulatory strategy advanced with March 25, 2026 FDA submission for GraftAssureDx, described as first kitted dd-cfDNA assay sent for review via Class II de novo pathway.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL9Kb3Cg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","LU2210149790.SGD","BK4082","LU2210150020.SGD","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","NDAQ","BK4585","IE00BKPKM429.USD","IMDX","MDIT","IE00B64PRP62.GBP","LU0314104364.USD","SG9999014039.USD","BK4139","SG9999014013.SGD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622582450","title":"Analysts Are Bullish on Top Healthcare Stocks: Insight Molecular Diagnostics (IMDX), Tango Therapeutics (TNGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622582450","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622582450?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:50","pubTimestamp":1774615848,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insight Molecular Diagnostics (IMDX), Tango Therapeu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-insight-molecular-diagnostics-imdx-tango-therapeutics-tngx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-insight-molecular-diagnostics-imdx-tango-therapeutics-tngx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4112","LABU","BK4588","BLSX","BK4137","BLSG","BK4585","XBI","BK4139","IMDX","TNGX","LU0128526141.USD","BK4581","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622847173","title":"Buy Rating on IMDX Driven by Strong GraftAssure Traction, Upcoming FDA Catalyst, and Solid Balance Sheet","url":"https://stock-news.laohu8.com/highlight/detail?id=2622847173","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622847173?lang=en_us&edition=fundamental","pubTime":"2026-03-27 17:55","pubTimestamp":1774605320,"startTime":"0","endTime":"0","summary":"Analyst Michael Matson of Needham maintained a Buy rating on Insight Molecular Diagnostics, retaining the price target of $9.00. Michael Matson has...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-imdx-driven-by-strong-graftassure-traction-upcoming-fda-catalyst-and-solid-balance-sheet-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-imdx-driven-by-strong-graftassure-traction-upcoming-fda-catalyst-and-solid-balance-sheet-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMDX","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622989625","title":"Insight Molecular Q4 Adj. EPS $(0.27) Misses $(0.24) Estimate, Sales $1.139M Down From $1.486M Last Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2622989625","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622989625?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:10","pubTimestamp":1774555805,"startTime":"0","endTime":"0","summary":"Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.24) by 13.92 percent. This is a 3.57 percent increase over losses of $(0.28) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51495180/insight-molecular-q4-adj-eps-0-27-misses-0-24-estimate-sales-1-139m-down-from-1-486m-last-year","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Insight Molecular Q4 Adj. EPS $(0.27) Misses $(0.24) Estimate, Sales $1.139M Down From $1.486M Last Year","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622466896","title":"Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622466896","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622466896?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:09","pubTimestamp":1774555787,"startTime":"0","endTime":"0","summary":"iMDx published a shareholder letter alongside its fourth-quarter and full-year 2025 financial results, reporting full-year revenue of USD 4.1 million, up 115.8% year over year.Fourth-quarter revenue was USD 1.1 million, with gross profit of USD 496,000 and gross margin of 43.5%.Operating expenses in the quarter were USD 23.9 million, including USD 14.6 million of non-cash intangible asset impairment losses.Net loss for the quarter was USD 23.0 million, or USD 0.72 per share, while adjusted net loss was USD 8.7 million, or USD 0.27 per share.Management said it submitted the GraftAssureDx kidney transplant rejection test for FDA review and is planning for an FDA-authorized product this year, while guiding to average cash burn of about USD 7.5 million per quarter in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL7Y4TcY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDIT","IMDX","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622899372","title":"Insight Molecular Diagnostics Inc - Reports Q4 2025 Net Loss of $23.0 Mln or $0.72 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2622899372","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622899372?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUASJM1F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":56,"code":"91000000","status":"200"}]}}